BIBLIOGRAFÍA Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(3):291–322. doi:10.1086/649858 Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of disease of HIV- associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17(8):873–881. doi:10.1016/S1473- 3099(17)30243- 8 Williamson PR, Jarvis JN, Panackal AA, Fisher MC, epidemiology, immunology, diagnosis and Molloy SF, therapy. Loyse A, et al. Cryptococcal meningitis: Nat Rev Neurol. 2017;13(1):13–24. doi:10.1038/nrneurol.2016.167 Boulware DR, Rolfes MA, Rajasingham R, von Hohenberg M, Qin Z, Taseera K, et al. Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast. Emerg Infect Dis. 2014;20(1):45–53. doi:10.3201/eid2001.130818 Rothe C, Sloan DJ, Goodson P, Chiller T, Kwizera R, Meya D, et al. A simplified diagnostic model for HIV- associated cryptococcal meningitis in resource- limited settings. Clin Infect Dis. 2013;56(5):587–593. doi:10.1093/cid/cis916 Rhein J, Hullsiek KH, Tugume L, Nuwagira E, Mpoza E, Evans EE, et al. Adjunctive sertraline in HIV- associated cryptococcal meningitis: a randomized clinical trial. Open Forum Infect Dis. 2016;3(3):ofw090. doi:10.1093/ofid/ofw090 Sloan DJ, Parris V. Cryptococcal meningitis: epidemiology and therapeutic options. Clin Epidemiol. 2014;6:169– 182. doi:10.2147/CLEP.S38850 .